Dont think this is a pump and dump, unless the ch9 coverage was...

Dont think this is a pump and dump, unless the ch9 coverage was the pump.

This stock, like MMR is fairly thinly held and hence quite volatile. Also BPH has some shareholders frustrated by DB's change of direction away from bio to energy which hasn't helped the stock either IMO.

So up around 20% in past week, 40% in two weeks and suspect it is from the ch9 coverage, particularly as regards upcoming Bonaparte activity.

Believe BPH is still undervalued, especially if compared to MMR. Optus has reduced my juice as family used it all this month so can't look up latest Advent holdings but from memory BPH up around 28-30% and MMR 50%. So given MMR market cap of $45M, BPH at $13M still looks cheap.

I've spoken with David Breeze a couple of times this year. He explains that Bonaparte is less risky than PEP11 and drilling could add shareholder fairly quickly while they finalise their review of PEP11 and plan the next campaign. The last announcement outlines all this and the ch9 clip summarises.

This is one of the worst performers in my portfolio (along with CTP and ROG, am free carried with my MMR and GBA holdings), but hanging in for Bonaparte while still see PEP11 as the main game. Being from the medical industry, see bios as more risky than energy, especially in the Asian growth context today.

Looking forward to their next announcement and best of luck all holders.